EUVIMEDEUVIMED entdecken
Crossref

Development of Novel Cholecystokinin 2 Receptor-Targeted Radioligand Containing Albumin Binder for Efficient 111 In/ 177 Lu Theranostics

Takahiro Yamamoto, Kazuma Nakashima iD, Nobuki Kazuta, Hiroyuki Watanabe iD, Masahiro Ono iD

Bioconjugate Chemistry · 2026

DOI: 10.1021/acs.bioconjchem.6c00272 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioconjugate Chemistry, 2026. Verfasst von Takahiro Yamamoto und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Patho-Functional Bioanalysis, Graduate School of Pharmaceutical Sciences, Kyoto University, Sakyo-ku, Kyoto 606-8501, Japan. Hauptthemen laut MEDLINE: Receptor, Cholecystokinin B, Lutetium, Indium Radioisotopes, Radiopharmaceuticals. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: F-REI.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Theranostics, an integrated approach combining cancer diagnosis and therapy, has gained increasing attention, particularly in the field of radiotheranostics using radioligands. The cholecystokinin 2 receptor (CCK2R), which is overexpressed in various neuroendocrine tumors (NETs), is considered a promising target for radiotheranostic applications. However, the currently available CCK2R-targeted ligand, DOTA-MGS5, exhibits limited tumor accumulation. Incorporation of an albumin binder (ALB) unit, which is capable of interacting with serum albumin, has been reported to enhance tumor accumulation of radioligands by prolonging their biological half-lives. To establish a more efficient CCK2R-targeted radiotheranostic strategy, we developed a novel CCK2R-targeted ALB-containing radioligand, [111In]In/[177Lu]Lu-MGS5-DA, based on DOTA-MGS5. In biodistribution studies, [111In]In-MGS5-DA showed markedly higher tumor accumulation compared with [111In]In-DOTA-MGS5. Moreover, single-photon emission computed tomography/computed tomography (SPECT/CT) imaging confirmed that [111In]In-MGS5-DA could be used to clearly visualize CCK2R-expressing tumors. In a peptide receptor radionuclide therapy (PRRT) study, [177Lu]Lu-MGS5-DA led to greater tumor growth inhibition than [177Lu]Lu-DOTA-MGS5. These findings suggest that [111In]In/[177Lu]Lu-MGS5-DA is a promising radiotheranostic pair for the treatment of CCK2R-expressing cancers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptor, Cholecystokinin BLutetiumIndium RadioisotopesRadiopharmaceuticalsRadioisotopesTheranostic NanomedicineNeuroendocrine TumorsAnimalsHumansMiceLigandsTissue DistributionCell Line, Tumor

Substanzen

Receptor, Cholecystokinin BLutetiumIndium RadioisotopesLutetium-177RadiopharmaceuticalsRadioisotopesLigands

Autor:innen und Institutionen

  • Department of Patho-Functional Bioanalysis, Graduate School of Pharmaceutical Sciences, Kyoto University, Sakyo-ku, Kyoto 606-8501, Japan.

ORCID-Profile: Kazuma Nakashima, Hiroyuki Watanabe, Masahiro Ono

Förderung

  • F-REI

Zitieren

APA

Yamamoto, T., Nakashima, K., Kazuta, N., Watanabe, H., & Ono, M. (2026). Development of Novel Cholecystokinin 2 Receptor-Targeted Radioligand Containing Albumin Binder for Efficient 111 In/ 177 Lu Theranostics. Bioconjugate Chemistry. https://doi.org/10.1021/acs.bioconjchem.6c00272

Vancouver

Yamamoto T, Nakashima K, Kazuta N, Watanabe H, Ono M. Development of Novel Cholecystokinin 2 Receptor-Targeted Radioligand Containing Albumin Binder for Efficient 111 In/ 177 Lu Theranostics. Bioconjugate Chemistry. 2026. doi:10.1021/acs.bioconjchem.6c00272

BibTeX
@article{Yamamoto2026,
  author = {Yamamoto, Takahiro and Nakashima, Kazuma and Kazuta, Nobuki and Watanabe, Hiroyuki and Ono, Masahiro},
  title = {Development of Novel Cholecystokinin 2 Receptor-Targeted Radioligand Containing Albumin Binder for Efficient 111 In/ 177 Lu Theranostics},
  journal = {Bioconjugate Chemistry},
  year = {2026},
  doi = {10.1021/acs.bioconjchem.6c00272}
}
Kostenlos starten →